# A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

> **NCT05139680** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

## Interventions

- **DRUG:** tafamidis

## Key facts

- **NCT ID:** NCT05139680
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-08
- **Primary completion:** 2023-05-19
- **Final completion:** 2023-05-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139680, "A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05139680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*